Robert J. Arceci

Robert J. Arceci's AcademicInfluence.com Rankings

Robert J. Arceci

Philosophy

#3514

World Rank

#5666

Historical Rank

Logic

#1201

World Rank

#1892

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Robert J. Arceci's Degrees

Masters Medicine University of California, San Francisco

Why Is Robert J. Arceci Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Robert J. Arceci's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing (2012) (1129)
Biology, risk stratification, and therapy of pediatric acute leukemias: an update. (2011) (792)
Mouse GATA-4: a retinoic acid-inducible GATA-binding transcription factor expressed in endodermally derived tissues and heart (1993) (752)
Apparent role of the macrophage growth factor, CSF-1, in placental development (1987) (510)
The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues (1989) (481)
PML targeting eradicates quiescent leukaemia-initiating cells (2009) (404)
The multidrug resistance (mdr1) gene product functions as an ATP channel. (1993) (359)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study (2009) (293)
Temporal expression and location of colony-stimulating factor 1 (CSF-1) and its receptor in the female reproductive tract are consistent with CSF-1-regulated placental development. (1989) (289)
The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report (2009) (283)
Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. (1989) (283)
Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. (1995) (277)
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. (2006) (272)
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia (2010) (271)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response (2008) (259)
The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. (1988) (258)
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. (2008) (257)
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA (2010) (243)
Localized expression of the atrial natriuretic factor gene during cardiac embryogenesis. (1987) (231)
Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial (2011) (226)
Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance. (1998) (224)
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. (2008) (224)
Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. (2009) (222)
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. (2003) (219)
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study (2010) (206)
The incidence and clinical significance of nucleophosmin mutations in childhood AML. (2007) (206)
Medical Care in Long-Term Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study (2009) (201)
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival (2012) (197)
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma (2010) (196)
Growth retardation and premature aging phenotypes in mice with disruption of the SNF2-like gene, PASG. (2004) (190)
Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. (2002) (182)
Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. (2011) (176)
Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia (2012) (175)
Treatment of congenital osteopetrosis with high-dose calcitriol. (1984) (171)
Evolution of human BCR–ABL1 lymphoblastic leukaemia-initiating cells (2011) (169)
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. (2010) (165)
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia (2012) (162)
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. (1990) (161)
The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. (2008) (157)
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone (2006) (156)
The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers (2007) (155)
Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. (2003) (149)
mdr2 encodes P-glycoprotein expressed in the bile canalicular membrane as determined by isoform-specific antibodies. (1992) (147)
Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. (2001) (145)
Allograft inflammatory factory-1. A cytokine-responsive macrophage molecule expressed in transplanted human hearts. (1996) (141)
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. (2006) (140)
Development of Risk-Based Guidelines for Pediatric Cancer Survivors: The Children's Oncology Group Long-term Follow-up Guidelines From the Children's Oncology Group Late Effects Committee and Nursing Discipline (2006) (136)
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. (2005) (134)
Absence of colony-stimulating factor-1 in osteopetrotic (csfmop/csfmop) mice results in male fertility defects. (1996) (134)
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes (2011) (134)
A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia (2012) (131)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias (2011) (127)
Ribosomal protein gene deletions in Diamond-Blackfan anemia. (2011) (126)
Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891 (2005) (125)
The histiocytoses: the fall of the Tower of Babel. (1999) (124)
Familial clustering of Langerhans cell histiocytosis (1999) (124)
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD–specific STAT5 activation (2010) (124)
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. (2005) (123)
Controversies and new approaches to treatment of Langerhans cell histiocytosis. (1998) (116)
Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study (2011) (116)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial (2008) (116)
Central nervous system disease in Langerhans cell histiocytosis. (2010) (115)
Atypical cellular disorders. (2002) (113)
Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. (1993) (108)
Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia (2011) (107)
Role of colony stimulating factor‐1 (CSF‐1) and other lympho‐hematopoietic growth factors in mouse pre‐implantation development (1991) (107)
Allelotype of pediatric rhabdomyosarcoma (1997) (107)
Clonal relationship between precursor T-lymphoblastic leukaemia/lymphoma and Langerhans-cell histiocytosis. (2005) (106)
Error reduction in pediatric chemotherapy: computerized order entry and failure modes and effects analysis. (2007) (105)
Phase I Pharmacokinetic and Pharmacodynamic Study of 17-N-Allylamino-17-Demethoxygeldanamycin in Pediatric Patients with Recurrent or Refractory Solid Tumors: A Pediatric Oncology Experimental Therapeutics Investigators Consortium Study (2007) (105)
Targeting cell cycle regulators in hematologic malignancies (2015) (103)
Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641 (2012) (101)
Expression of CSF-1/c-fms and SF/c-kit mRNA during preimplantation mouse development. (1992) (100)
Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. (1996) (99)
An Integrated Genomic Analysis of Human Glioblastoma Multiforme (2009) (98)
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. (2003) (94)
Multidrug resistance gene expression is controlled by steroid hormones in the secretory epithelium of the uterus (1990) (94)
2′‐chlorodeoxyadenosine (2‐CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH‐S‐98 protocol of the histiocyte society (2009) (93)
Results of the EICESS-92 Study: Two Randomized Trials of Ewing's Sarcoma Treatment—Cyclophosphamide Compared With Ifosfamide in Standard-Risk Patients and Assessment of Benefit of Etoposide Added to Standard Treatment in High-Risk Patients (2009) (92)
Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. (2010) (91)
Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. (2004) (90)
The genetic basis of early T–cell precursor acute lymphoblastic leukaemia (2012) (90)
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia (2012) (89)
STAT3 activation is required for Asp816 mutant c-Kit induced tumorigenicity (2001) (89)
End points to establish the efficacy of new agents in the treatment of acute leukemia. (2007) (87)
Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group. (2008) (81)
ERBB4 confers metastatic capacity in Ewing sarcoma (2013) (80)
Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group (2010) (80)
Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2‐chlorodeoxyadenosine (2008) (80)
Atypical Teratoid/Rhabdoid Tumors (ATRT): Improved Survival in Children 3 Years of Age and Older With Radiation Therapy and High-Dose Alkylator-Based Chemotherapy (2006) (80)
Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951. (2003) (80)
Proliferation-associated SNF2-like gene (PASG): a SNF2 family member altered in leukemia. (2000) (77)
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning (2011) (77)
Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. (2006) (76)
Biology of Langerhans cells and Langerhans cell histiocytosis. (2006) (75)
RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors (2012) (75)
Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. (2006) (75)
Age-Related Prognostic Impact of Different Types of DNMT3A Mutations in Adults With Primary Cytogenetically Normal Acute Myeloid Leukemia (2012) (74)
Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P‐glycoprotein (1993) (72)
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome (2010) (71)
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia (2003) (70)
Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1 (2015) (70)
Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97 (2009) (67)
Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. (1995) (66)
Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia (2012) (65)
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes—A Report From the Children's Oncology Group (2012) (65)
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced‐dose chemotherapy on Children's Oncology Group trial A2971 (2012) (64)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial (2011) (64)
Fusion Gene–Negative Alveolar Rhabdomyosarcoma Is Clinically and Molecularly Indistinguishable From Embryonal Rhabdomyosarcoma (2010) (64)
Error Reduction in Pediatric Chemotherapy: Computerized Order Entry and Failure Modes and Effects AnalysisKim GR, Chen AR, Arceci RJ, et al (Johns Hopkins School of Medicine, Baltimore, Md) Arch Pediatr Adolesc Med 160:495–498, 2006§ (2006) (62)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients (2010) (61)
The programmed switch in lysine-rich histone synthesis at gastrulation (1976) (61)
PAX3/FOXO1 Fusion Gene Status Is the Key Prognostic Molecular Marker in Rhabdomyosarcoma and Significantly Improves Current Risk Stratification (2012) (60)
Congenital and neonatal leukemia. (1999) (60)
When T cells and macrophages do not talk: the hemophagocytic syndromes (2008) (58)
Wilms tumor suppressor WTX negatively regulates WNT/β-catenin signaling (2008) (58)
Histone variants and chromatin structure during sea urchin development. (1980) (57)
The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA (2010) (56)
Mutations of E3 Ubiquitin Ligase Cbl Family Members Constitute a Novel Common Pathogenic Lesion in Myeloid Malignancies (2010) (56)
Exploiting pre‐rRNA processing in Diamond Blackfan anemia gene discovery and diagnosis (2014) (56)
Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated? (1997) (55)
Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. (1999) (55)
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. (2009) (55)
Significant responses to platinum‐based chemotherapy in renal medullary carcinoma (2005) (53)
Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia (2009) (53)
Constitutive expression of multidrug resistance in human colorectal tumours and cell lines. (1993) (52)
Lsh regulates LTR retrotransposon repression independently of Dnmt3b function (2013) (51)
Induction of embryonic vasculogenesis by bFGF and LIF in vitro and in vivo. (1996) (51)
Neutrophil defect associated with malignant infantile osteopetrosis. (1986) (50)
Gene Expression Signatures Identify Rhabdomyosarcoma Subtypes and Detect a Novel t(2;2)(q35;p23) Translocation Fusing PAX3 to NCOA1 (2006) (50)
Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. (2000) (50)
The Nikolas Symposia and histiocytosis (2005) (50)
Universal Poor Survival in Children With Medulloblastoma Harboring Somatic TP53 Mutations (2010) (49)
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile (2012) (49)
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group (2011) (48)
Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein (2009) (48)
Identification and upregulation of galactose/N-acetylgalactosamine macrophage lectin in rat cardiac allografts with arteriosclerosis. (1994) (46)
Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification (2010) (46)
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. (2007) (46)
Phase II/III trial of a pre‐transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: A report from the Children's Oncology Group (2015) (44)
Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia (2012) (44)
Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study (2012) (44)
Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2–mediated resistance (2009) (43)
P-Glycoprotein conformational changes detected by antibody competition. (2001) (43)
Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. (2009) (43)
Distinct ribosome maturation defects in yeast models of Diamond-Blackfan anemia and Shwachman-Diamond syndrome (2010) (42)
Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease (2009) (42)
Langerhans cell histiocytosis is a neoplasm and consequently its recurrence is a relapse: In memory of Bob Arceci (2016) (41)
Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (2009) (41)
Progress and controversies in the treatment of pediatric acute myelogenous leukemia (2002) (40)
Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology Patients. (2012) (40)
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group (2011) (40)
Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century (2009) (39)
Anti-B4-blocked ricin synergizes with doxorubicin and etoposide on multidrug-resistant and drug-sensitive tumors. (1995) (38)
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA (2011) (37)
Whole-Genome Profiling of Pediatric Diffuse Intrinsic Pontine Gliomas Highlights Platelet-Derived Growth Factor Receptor α and Poly (ADP-ribose) Polymerase As Potential Therapeutic Targets (2010) (37)
Tumor Origin of Endothelial Cells in Human Neuroblastoma (2008) (36)
An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma (2009) (36)
An SNF2 factor involved in mammalian development and cellular proliferation (2001) (35)
WT1 expression at diagnosis does not predict survival in pediatric aml: A report from the Children's Oncology Group (2009) (35)
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma (2008) (35)
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib (2010) (35)
Activating mutations in human acute megakaryoblastic leukemia (2009) (34)
Notch Pathway Inhibition Depletes Stem-like Cells and Blocks Engraftment in Embryonal Brain Tumors (2008) (33)
Granulocyte-macrophage colony-stimulating factor and interleukin-3 mRNAs are produced by a small fraction of blood mononuclear cells. (1989) (33)
Phase I study of valspodar (PSC‐833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group (2010) (33)
The histiocytoses of infancy. (1999) (33)
A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study (2011) (33)
Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: Impact on WHO classification (2007) (33)
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells (2017) (32)
Final Results of a Prospective Clinical Trial With VAMP and Low-Dose Involved-Field Radiation for Children With Low-Risk Hodgkin's Disease (2008) (32)
Can multidrug resistance mechanisms be modified? (2000) (31)
Successful treatment of a child with late onset T‐cell post‐transplant lymphoproliferative disorder/lymphoma (2008) (30)
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004) (2010) (30)
Flow cytometric findings in hemophagocytic lymphohistiocytosis. (2012) (30)
P-glycoprotein mediates profound resistance to bisantrene. (1994) (29)
Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: A report from the Children's Oncology Group (2011) (27)
Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice (2011) (27)
Noncoincidence of histone and DNA synthesis in cleavage cycles of early development. (1977) (27)
Clofarabine in pediatric acute leukemia: Current findings and issues (2012) (27)
Sea urchin sperm chromatin structure as probed by pancreatic DNase I: evidence for a noval cutting periodicity. (1980) (26)
WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system (2010) (26)
Telomere length shortening in Langerhans cell histiocytosis (2008) (25)
Improved Outcome of Acute Promyelocytic Leukemia With High WBC Counts Over the Last 15 Years: The European APL Group Experience (2009) (25)
The changing face of clinical trials (2004) (25)
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. (2007) (25)
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML (2017) (24)
Pediatric oncology: A comprehensive guide (2006) (24)
Expression and ontogeny of murine CD2 (1989) (24)
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital (2010) (24)
Genomic Analysis of the Clonal Origins of Relapsed Acute Lymphoblastic Leukemia (2009) (23)
National Action Plan for Childhood Cancer: Report of the National Summit Meetings on Childhood Cancer * (2002) (23)
Survival after T cell–depleted haploidentical stem cell transplantation is improved using the mother as donor (2009) (23)
BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group (2011) (23)
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors (2011) (22)
Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: A prospective multi‐institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA) (2014) (22)
Tumor cell survival and resistance to therapy (1996) (22)
BRAF, a piece of the LCH puzzle. (2010) (21)
COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML) (2008) (20)
Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes. (2001) (20)
The International Prognostic Scoring System (IPSS) for Childhood Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML) (2006) (19)
Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line (2015) (19)
Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial (2008) (19)
Mechanisms of resistance to therapy and tumor cell survival (1995) (19)
Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial (2010) (19)
The Question of God: C.S. Lewis and Sigmund Freud Debate God, Love, Sex, and the Meaning of Life. (2003) (19)
The Beginning of the Road for Non-Coding RNAs in Normal Hematopoiesis and Hematologic Malignancies (2011) (19)
Cancer Genomics: From Bench to Personalized Medicine (2013) (19)
Role and expression of colony stimulating factor-1 and steel factor receptors and their ligands during pregnancy in the mouse (1992) (18)
A phase IIa study of afuresertib, an oral pan‐AKT inhibitor, in patients with Langerhans cell histiocytosis (2017) (18)
Update in childhood acute myeloid leukemia: recent developments in the molecular basis of disease and novel therapies (2003) (18)
A Neurologic Presentation of Familial Hemophagocytic Lymphohistiocytosis Which Mimicked Septic Emboli to the Brain (2007) (18)
Soft Tissue Sarcoma or Malignant Mesenchymal Tumors in the First Year of Life: Experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee (2007) (18)
Histone gene expression: progeny of isolated early blastomeres in culture make the same change as in the embryo. (1980) (18)
Treatment of high risk medulloblastomas in children above the age of 3 years: A SFOP study (2008) (17)
Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome. (2013) (17)
Consistent Deregulation of Gene Expression between Human and Murine MLL Rearrangement Leukemias (2009) (17)
Stable knockdown of PASG enhances DNA demethylation but does not accelerate cellular senescence in TIG-7 human fibroblasts (2008) (17)
Colony-Stimulating Factor I in the Mouse and Human Uteroplacental Unit (1991) (17)
FLT3 internal tandem duplication in CD34+/CD33− precursors predicts poor outcome in acute myeloid leukemia (2008) (17)
Long-term Visual Outcome Following Chemoreduction for Retinoblastoma (2007) (17)
Anti–Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials (2012) (16)
Strategies for the Prevention of Central Nervous System Complications in Patients with Langerhans Cell Histiocytosis: The Problem of Neurodegenerative Syndrome. (2015) (16)
Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study (2012) (16)
Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group (2012) (16)
Outlier Analysis and Top Scoring Pair for Integrated Data Analysis and Biomarker Discovery (2014) (16)
The potential for antitumor vaccination in acute myelogenous leukemia (1998) (15)
Biological and therapeutic implications of the BRAF pathway in histiocytic disorders. (2014) (15)
What is the optimal therapy for childhood AML? (2002) (15)
NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS) (2009) (15)
Langerhans cell histiocytosis: an uncommon disease commonly manifesting in the craniofacial skeleton. (1996) (15)
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group (2007) (14)
In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells (2019) (14)
Immunosurveillance and survivin-specific T-cell immunity in children with high-risk neuroblastoma (2008) (14)
Pediatric histiocytosis. Characterization, prognosis, and oral involvement. (1993) (14)
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD 33 acute myeloid leukemia (2005) (14)
Improved Outcome for Children With Acute Lymphoblastic Leukemia: Results of Total Therapy Study XIIB at St Jude Children's Research Hospital (2006) (14)
Assessment of BCR-ABL1 Transcript Levels at 3Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors (2012) (13)
Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group (2008) (13)
EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma (2010) (13)
Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group (2011) (13)
Phase II Trials of Clofarabine in Relapsed or Refractory Pediatric Leukemia. (2004) (13)
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis (2018) (13)
Outcome of Down Syndrome (DS) Children with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Treated with a Uniform Prospective Clinical Trial - Initial Report of the COG Trial A2971. (2006) (12)
Pediatric Hematology: Third Edition (2007) (12)
Successful Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive Lymphadenopathy Using Sirolimus (2016) (12)
Histones of sea urchin embryos. Transients in transcription, translation, and the composition of chromatin. (1978) (12)
Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project (2012) (12)
Benzquinamide inhibits P-glycoprotein mediated drug efflux and potentiates anticancer agent cytotoxicity in multidrug resistant cells. (1992) (11)
HTLV-III infection after bone marrow transplantation. (1986) (11)
AIDA0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance (2011) (11)
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders (2010) (11)
Phage display generation of a novel human anti‐CD1A monoclonal antibody with potent cytolytic activity (2012) (11)
High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia (2009) (11)
Misinterpretation of a Calvert-derived formula leading to carboplatin overdose in two children. (2003) (11)
The art and science of writing manuscripts (2004) (10)
Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study (2012) (10)
A multi‐center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors (2013) (10)
Pre-Enucleation Chemotherapy for Eyes Severely Affected by Retinoblastoma Masks Risk of Tumor Extension and Increases Death From Metastasis (2012) (10)
Hematopoietic Stem Cell Transplantation (HSCT) in Children With Juvenile Myelomonocytic Leukemia (JMML): Results of the EWOG-MDS/EBMT Trial (2006) (10)
Surviving childhood cancer: A special series on the successes and challenges after “Cure” (2006) (10)
Cytokines at the Maternal Fetal Interface: Colony Stimulating Factor-1 as a Paradigm for the Maternal Regulation of Pregnancy (1991) (9)
Comments from the Editor‐in‐Chief (1998) (9)
Position Statement for the Need to Define Pediatric Hematology/Oncology Programs: A Model of Subspecialty Care for Chronic Childhood Diseases (1998) (9)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome (2012) (9)
Treatment of Anaplastic Histology Wilms' Tumor: Results From the Fifth National Wilms' Tumor Study (2008) (9)
Emerging cancer-targeted therapies. (2002) (9)
Identification of Novel Somatic Mutations, Regions of Recurrent Loss of Heterozygosity (LOH) and Significant Clonal Evolution From Diagnosis to Relapse in Childhood AML Determined by Exome Capture Sequencing – an NCI/COG Target AML Study (2012) (9)
Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma (2006) (9)
Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study (2011) (9)
Evaluation Of Afuresertib, An Oral Pan-AKT Inhibitor, In Patients With Langerhans Cell Histiocytosis (2013) (9)
Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98 (2008) (9)
Altered Epigenetic Patterning Leading to Replicative Senescence and Reduced Longevity: A Role of a Novel SNF2 Factor, PASG (2005) (9)
Integrative Genomics Identifies Distinct Molecular Classes of Neuroblastoma and Shows That Multiple Genes Are Targeted by Regional Alterations in DNA Copy Number (2008) (9)
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group (2009) (8)
Differentiation responses of embryonic endothelium to leukemia inhibitory factor. (1998) (8)
Antitumor Effects of a Combined 5-Aza-2′Deoxycytidine and Valproic Acid Treatment on Rhabdomyosarcoma and Medulloblastoma in Ptch Mutant Mice (2009) (8)
Modulation of MDR‐1 expression by a H‐ras oncogene in a human colon carcinoma cell line (1993) (8)
Molecularly targeted therapy for childhood cancer (2010) (8)
Non-Hodgkin Lymphoma of Childhood (2013) (8)
Generation of induced pluripotent stem cells from human blood (2009) (8)
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations (2010) (8)
Silencing of SPRY1 Triggers Complete Regression of Rhabdomyosarcoma Tumors Carrying a Mutated RAS Gene (2010) (8)
Lymphokine expression profile of resting and stimulated CD4+ CTL clones specific for the glycoprotein of vesicular stomatitis virus. (1993) (7)
DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications (2012) (7)
High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia (2008) (7)
Pediatric blood and cancer at age 3.5 years (2007) (7)
Infectious complications of intensive chemotherapy on children's cancer group protocol CCG-2961 for pediatric acute myeloid leukemia (2002) (7)
Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007 (2012) (7)
Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia (2011) (7)
High Risk of Symptomatic Cardiac Events in Childhood Cancer Survivors (2012) (6)
P-glycoprotein is expressed in the mineralizing regions of the skeleton (1996) (6)
Hospital and home chemotherapy for children with leukemia: a randomized cross-over study (2008) (6)
Prognostic significance of the initial cerebro-spinal fluid (CSF) involvement of children with acute lymphoblastic leukaemia (ALL) treated without cranial irradiation: Results of European Organization for Research and Treatment of Cancer (EORTC) Children Leukemia Group study 58881 (2011) (6)
Twelve it is (2003) (6)
Gene Expression Profiling of Human Sarcomas: Insights into Sarcoma Biology (2007) (6)
A gamma delta+ T-cell leukemia bearing a novel t(8;14)(q24;q11) translocation demonstrates spontaneous in vitro natural killer-like activity. (1992) (6)
Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia (2009) (6)
5q- Myelodysplastic Syndrome, In One of 23 Children Lacking a Known Ribosomal Gene Mutation, Masquerading as Diamond Blackfan Anemia (DBA) and Responding to Lenalidomide (2010) (6)
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study (2011) (6)
The utility of computed tomography in the management of fever and neutropenia in pediatric oncology (2015) (6)
Conformational heterogeneity of P-glycoprotein. (2000) (6)
Identification of ALK as the Major Familial Neuroblastoma Predisposition Gene (2009) (6)
Treatment options--commentary. (1994) (5)
A Large Ribosomal Subunit Protein Abnormality in Diamond-Blackfan Anemia (DBA). (2007) (5)
Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols (2012) (5)
Inpatient Versus Outpatient Management of Low-Risk Pediatric Febrile Neutropenia: Measuring Parents' and Healthcare Professionals' PreferencesSung L, Feldman BM, Schwamborn G, et al (Univ of Toronto; Hosp for Sick Children, Toronto; Dartmouth Med School, Hanover, NH) J Clin Oncol 22:3922–3929, 2004§ (2006) (5)
Clonal selection drives genetic divergence of metastatic medulloblastoma (2012) (5)
Comparable Long-Term Survival After Unrelated and HLA-Matched Sibling Donor Hematopoietic Stem Cell Transplantations for Acute Leukemia in Children Younger Than 18 Months (2007) (4)
Single Cell Network Profiling (SCNP) Signatures Predict Response to Induction Therapy and Relapse Risk In Pediatric Patients with Acute Myeloid Leukemia: Children's Oncology Group (COG) Study POG-9421 (2010) (4)
Summary of the 12th Nikolas Symposium dendritic cell differentiation: signals, signaling and functional consequences as clues to possible therapy. (2003) (4)
Genome Wide Promoter Methylation Patterns Predict AML Subtype Outcomes and Identify Novel Pathways Characterizing Diagnostic and Relapsed Disease in Children (2012) (4)
Impact of the Methotrexate Administration Dose on the Need for Intrathecal Treatment in Children and Adolescents With Anaplastic Large-Cell Lymphoma: Results of a Randomized Trial of the EICNHL Group (2009) (4)
Abstract LB-212: Treehouse Childhood Cancer Project: a resource for sharing and multiple cohort analysis of pediatric cancer genomics data (2015) (4)
Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA GroupOrtega JJ, Madero L, Martín G, et al (Hosp Universitario Materno-Infantil Vall D'Hebron, Barcelona; Hosp Niĩno Jesús, Madrid; Hosp Univers (2007) (4)
Dendritic cell disorders: matters of lineage and clinical drug testing in rare diseases. (2015) (4)
Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment (2012) (4)
6-Thioguanine reactivates epigenetically silenced genes in acute lymphoblastic leukemia cells by facilitating proteasome-mediated degradation of DNMT1 (2011) (4)
Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 (2010) (4)
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYCLi X-N, Shu Q, Su J M-F, et al (Baylor College of Medicine, Houston) Mol Cancer Ther 4:1912–1922, 2005§ (2007) (4)
Clinically Significant Mutations, Deletions and Translocations Involving ETV6 Identified by Whole Genome and Whole Exome Sequencing; Report From NCI/COG Target AML Initiative (2012) (4)
Congenital Anomalies in the Children of Cancer Survivors: A Report From the Childhood Cancer Survivor Study (2012) (4)
Down syndrome, transient myeloproliferative syndrome, and leukemia: bridging development and neoplasia. (2002) (4)
Erratum: Ribosomal Protein Genes RPS10 and RPS26 Are Commonly Mutated in Diamond-Blackfan Anemia (DOI:10.1016/j.ajhg.2009.12.015) (2010) (4)
Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma (2010) (4)
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (2010) (4)
Acute Myeloid Leukemia in Children: A Review of Risk Factors and Recent Trials (2002) (3)
Comprar Pediatric oncology. A comprehensive guide | R. Arceci | 9783642203589 | Springer (2011) (3)
Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor (2009) (3)
Biology of Acute Myeloid Leukemia (2011) (3)
Setting the course for “Pediatric Blood & Cancer” (2004) (3)
Treatment and outcome of infants with acute myeloid leukemia. (2002) (3)
Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group Study (2007) (3)
Disseminated histiocytoses: Biomarkers beyond BRAFV600E. (2015) (3)
Clofarabine in Children with Refractory/Relapsed Acute Leukemia: Results of 2 Phase II Open Label Studies. (2006) (3)
Allele loss at 16q defines poorer prognosis Wilms tumour irrespective of treatment approach in the UKW1–3 clinical trials: A Children's Cancer and Leukaemia Group (CCLG) study (2009) (3)
Autosomal Recessive Diamond-Blackfan Anemia: Identification Of Mutations In MCM2 and Flnb (2013) (3)
SNP Array Genotyping Reveals Constitutional and Mosaic Losses of Ribosomal Protein Gene Regions In Patients with Diamond Blackfan Anemia without Ribosomal Protein Gene Mutations. (2010) (3)
Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics (2008) (3)
Study of the factors associated with recurrence in children with sacrococcygeal teratoma (2007) (3)
Outlier Gene Set Analysis Combined with Top Scoring Pair Provides Robust Biomarkers of Pathway Activity (2013) (3)
Pediatric Oncology: Psychosocial Care in Context (2016) (3)
Association of clinical and biological resistance with a novel mutation in MAP2K1 in a patient with Langerhans cell histiocytosis. (2016) (3)
Comprehensive Sequence Analysis of Relapse and Refractory Pediatric Acute Myeloid Leukemia Identifies miRNA and mRNA Transcripts Associated with Treatment Resistance - a Report from the COG/NCI-Target AML Initiative (2015) (3)
Abstract LB-93: Demonstration of significant clonal evolution from diagnosis to relapse in childhood AML determined by exome capture sequencing: an NCI/COG TARGET AML study (2012) (3)
Cell-Free Nucleic Acids Circulating in the Plasma of Colorectal Cancer Patients Induce the Oncogenic Transformation of Susceptible Cultured Cells (2010) (3)
DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development (2014) (3)
Frequency and Heritability of WT1 Mutations in Nonsyndromic Wilms' Tumor Patients: A UK Children's Cancer Study Group StudyLittle SE, Hanks SP, King-Underwood L, et al (Royal Marsden Hosp, Sutton, Surrey, England J Clin Oncol 22:4140-4146, 2004§ (2006) (2)
Mitoxantrone, Etoposide and Cyclosporine A Therapy for Relapsed and Refractory Acute Myelogenous Leukemia, A Pediatric Oncology Group Phase II Trial (1996) (2)
Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML) (2012) (2)
Comments from the editor-in-chief. Infectious complications of cancer treatment. Survivorship and treatment-related toxicities: how well are we doing? (2003) (2)
Wilms' Tumor in Adults: Results of the Society of Pediatric Oncology (SIOP) 93-01/Society for Pediatric Oncology and Hematology (GPOH) StudyReinhard H, Aliani S, Ruebe C, et al (Univ Hosp, Homburg/Saar, Germany; Univ Hosp, Kiel, Germany J Clin Oncol 22:4500-4506, 2004§ (2006) (2)
Response in osteosarcoma. Information you can't use...yet? (2003) (2)
Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia (2011) (2)
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML (2008) (2)
Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants (2012) (2)
The Year book of oncology (1989) (2)
The Genetic Landscape of the Childhood Cancer Medulloblastoma (2011) (2)
Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-analysis of Randomized Controlled TrialsSung L, Nathan PC, Lange B, et al (Univ of Toronto; Hosp for Sick Children, (2006) (2)
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1 (2011) (2)
Incidence and Clinical Significance of Nucleophosmin Mutations in Childhood AML: A Childrens Oncology Group Study. (2006) (2)
Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas (2007) (2)
Adipocytes Impair Leukemia Treatment in Mice (2010) (2)
Differential Patterns of MicroRNA Expression in Neuroblastoma Are Correlated with Prognosis, Differentiation, and Apoptosis (2008) (2)
ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling (2011) (2)
Predictive Value of the Pretreatment Extent of Disease System in Hepatoblastoma: Results From the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 StudyAronson DC, Schnater JM, Staalman CR, et al (Vrije Universiteit Med Ctr, Amsterdam; Universitäts-Kinderklinik, Inselspit (2006) (2)
Uniform Approach Better Defines Natural History of Transient Myeloproliferative Disorder (TMD) in Down Syndrome (DS) Neonates: Outcomes from Children’ Oncology Group (COG) Study A2971. (2006) (2)
Criteria for optimizing prognostic risk groups in pediatric cancer: analysis of data from the Children's Oncology Group (2008) (2)
Insulin-Like Growth Factor-I Receptor Expression Regulates Neuroblastoma Metastasis to Bone (2007) (2)
An Expression Signature Classifies Chemotherapy-Resistant Pediatric Osteosarcoma (2006) (2)
PIM3-SCO2 Fusion Is a Novel Transcription-Induced Chimera That Is Highly Prevalent In Childhood AML (2013) (2)
Predicting outcomes--not as easy as it looks. (2003) (2)
Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML (2010) (2)
TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia (2008) (2)
Testing new agents: can we move beyond DLT? (2002) (2)
Histiocytic Disorders (2021) (2)
Nuclear ErbB2 Enhances Translation and Cell Growth by Activating Transcription of Ribosomal RNA Genes (2011) (2)
The challenges of cancer survivorship (2004) (2)
Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias. (2004) (2)
Telomere Length Shortening in Langerhans Cell Histiocytosis. (2007) (1)
Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes (2012) (1)
Writing guidelines without a net: ECD. (2014) (1)
Abstract 3422: RNAi screening identifies FGFR4 as a modulator of growth and survival in Ewing sarcoma (2014) (1)
Minimal Disseminated Disease in High-Risk Burkitt's Lymphoma Identifies Patients With Different Prognosis (2012) (1)
Synergisitic and Antagonistic AML Cell Type-specific Responses to 5-Aza-2-deoxycitidine and 1-h-D-Arabinofuranoside. (2016) (1)
Activation of Akt Predicts Poor Outcome in Neuroblastoma (2008) (1)
Clinical resistance associatedwith a novelMAP2K1mutation in a patient with Langerhans cell histiocytosis (2018) (1)
Synergistic and antagonistic AML cell type-specific responses to 5-AZA-2’-Deoxycytidine and 1-H-D-Arabinofuranosylcytosine (2014) (1)
Pediatric Blood & Cancer: The first 5 years (2008) (1)
Faculty Opinions recommendation of Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. (2006) (1)
5q- Syndrome In a Child: Is This Acquired Diamond Blackfan Anemia (DBA)? (2010) (1)
Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma (2008) (1)
Clinical trials and tribulations. (2001) (1)
Robbing Peter to pay Paul? Financial reimbursement for chemotherapy. (2003) (1)
Abstract 1177: The majority of total nuclear-encoded non-ribosomal RNA in human normal and tumor cells is “dark matter” unannotated RNA (2011) (1)
Solid cancers after allogeneic hematopoietic cell transplantation (2009) (1)
Analysis of histiocytosis deaths in the US and recommendations for incidence tracking. (2010) (1)
Chapter 15. Histiocytic Disorders (2007) (1)
The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma (2007) (1)
Abstract 431: ErbB4 is a novel driver of metastasis and anoikis resistance in Ewing's sarcoma (2012) (1)
Abstract 2001: 5-Aza-2’-deoxycytidine and cytarabine mediate distinct effects on clonogenic growth, genome wide methylation and RNA expression in AML (2011) (1)
When "rare" is no excuse for progress. (2013) (1)
Abstract 3338: A role for FGFR4 in growth and survival of Ewing sarcoma cells (2017) (1)
Treatment of Children with Relapsed Acute Myeloid Leukemia with Gemtuzumab in Combination with Mitoxantrone and Cytarabine. (2005) (1)
Family history (FH) of women with breast cancer (BC) and acute myelogenous leukemia (AML). (2010) (1)
Cytarabine Dose of 36g/m2 Compared With 12g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study (2011) (1)
Nonmalignant Late Effects and Compromised Functional Status in Survivors of Hematopoietic Cell Transplantation (2012) (1)
Insights Into Diagnosis and Etiology of Diamond Blackfan Anemia by Analysis of Pre-rRNA Processing (2012) (1)
Chemotherapy-refractory cutaneous Langerhans cell histiocytosis treated with radiotherapy. (2011) (1)
Differential Down-Regulation of RPL35a in Human Bone Marrow Progenitors Demonstrates a p53 Independent Mechanism Mediating the Diamond Blackfan Anemia Phenotype. (2009) (1)
Phase II trials of clofarabine in pediatric acute leukemia (2005) (1)
Abstract B81: Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors. (2013) (1)
A Human Anti-CD1a Monoclonal Antibody for Targeted Immunotherapy in Langerhans Cell Histiocytosis and Hematologic Malignancies. (2005) (1)
Correlation of Somatic Mutation and Expression Identifies Genes Important in Human Glioblastoma Progression and Survival (2011) (1)
Official Journal of The American Society of Pediatric Hematology/Oncology (1999) (1)
Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study (2008) (1)
Histiocytic Disorders of Children and Adults: Treatment of relapsed and/or refractory Langerhans cell histiocytosis (2005) (1)
Melanoma in Children and Teenagers: An Analysis of Patients From the National Cancer Data Base (2008) (1)
Identification of AML1-ETO modulators by chemical genomics (2010) (1)
L Central Nervous System Disease in Langerhans Cell Histiocytosis (2010) (1)
Childhood, adolescent and young adult acute myeloid leukemias (2012) (1)
Chapter 17 – Acute Myeloid Leukemia (2014) (1)
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose MethotrexateMeyers PA, Schwartz CL, Krailo M, et al (Children's Oncology Group, Arcadia, Calif J Clin Oncol 23:2004-2011, 2005§ (2006) (1)
Chapter 20 – Histiocytosis Syndromes (2016) (1)
Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias (2004) (1)
A phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors (2007) (1)
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia (2009) (1)
Comments from the editor-in-chielf (2001) (1)
CpG Island Methylator Phenotype Is a Strong Determinant of Poor Prognosis in NeuroblastomasAbe M, Ohira M, Kaneda A, et al (Natl Cancer Ctr Research Inst, Tokyo; Univ of Tokyo; Chiba Cancer Ctr Research Inst, Japan) Cancer Res 65:828-834, 2005§ (2006) (1)
Comments from the editor-in-chief. (2003) (1)
Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants. (2008) (1)
A phase II study of amifostine in children with myelodysplastic syndrome: A report from the Children's Oncology Group study (AAML0121) (2011) (0)
Validation of Met as a Therapeutic Target in Alveolar and Embryonal RhabdomyosarcomaTaulli R, Scuoppo C, Bersani F, et al (Univ of Turin, Italy) Cancer Res 66:4742–4749, 2006§ (2007) (0)
Hematology/Oncology Clinics of North America: Preface (2001) (0)
advanced CD33+ acute myeloid leukemia Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with (2013) (0)
#649 The feasibility of outpatient high dose multiagent cytoreductive rpeparative therapy (CPT) in patients undergoin autologous stem cell transplantation (SCT) for Ewing's sarcoma (ES) (1998) (0)
Abstract 5181: Targeted knockdown of MYC in AML cells using G-quadruplex interacting small molecules (2017) (0)
Lsh regulates LTR retrotransposon repression independently of Dnmt3b function (2013) (0)
Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma (2008) (0)
Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulationsAndersson A, Olofsson T, Lindgren D, et al (Lund Univ, Sweden; Linköping Univ, Sweden) Proc Natl Acad Sci USA 102:19069–19074, 2005§ (2007) (0)
GABAergic System Gene Expression Predicts Clinical Outcome in Patients With NeuroblastomaRoberts SS, Mori M, Pattee P, et al (Oregon Health & Sciences Univ, Portland; Children's Hosp, Los Angeles; Children's Cancer Group, Arcadia, Calif) J Clin Oncol 22:4127-4134, 2004§ (2006) (0)
Important changes to instructions to authors (2009) (0)
Children's Oncology Group untreated pediatric acute myeloid leukemia (AML): a report from the Outcomes in CCG-2961, a Children's Oncology Group phase 3 trial for (2013) (0)
Genome-Wide Analysis of Epigenetic Silencing Identifies BEX1 and BEX2 as Candidate Tumor Suppressor Genes in Malignant Glioma (2007) (0)
Issue Information (2014) (0)
leukemia Endpoints to establish the efficacy of new agents in the treatment of acute (2013) (0)
Prognostic Factors After Relapse in Nonmetastatic Rhabdomyosarcoma: A Nomogram to Better Define Patients Who Can Be Salvaged With Further Therapy (2011) (0)
Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study (2010) (0)
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia (2008) (0)
Coordinate Changes In RNA Expression, Transcript Splicing, and DNA Methylation In Pediatric AML (2013) (0)
Abstract 4077: Application of drug sensitivity and resistance testing to identify novel therapeutic agents for Down syndrome patients with AML (2017) (0)
Issue Information (2014) (0)
Bone Marrow Transplantation for Acute Myeloid Leukemia in Children (2006) (0)
he Role of Cytotoxic Therapy with Hematopoietic tem Cell Transplantation in the Therapy of Acute yeloid Leukemia in Children : An Evidence-Based eview (2007) (0)
In Memory (2007) (0)
Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells (2017) (0)
Unconventional therapies: "eyes wide shut". (2000) (0)
Identification of OTX2 as a Medulloblastoma Oncogene Whose Product Can Be Targeted by All-Trans Retinoic Acid (2006) (0)
Abstract B24: Targeting promoter regions of oncogenic drivers in pediatric AML cells using G-quadruplex Interacting Drugs (GQIDs) (2016) (0)
Therapy for acute myeloid leukemia: Intensive timing of induction chemotherapy (2000) (0)
A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML (2017) (0)
EZH2 Is Essential for Glioblastoma Cancer Stem Cell Maintenance (2010) (0)
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group (2007) (0)
Primum Non Nocere—Reply (2006) (0)
The Neurofibromatosis Type 1 Tumor Suppressor Controls Cell Growth by Regulating Signal Transducer and Activator of Transcription-3 Activity In vitro and In vivo (2010) (0)
LOSS AND HOPE (2001) (0)
acute leukemia End points to establish the efficacy of new agents in the treatment of (2013) (0)
Undifferentiated hematopoietic cells are characterized by a genome-wide undermethylation dip around the transcription start site and a hierarchical epigenetic plasticity (2010) (0)
Contributors (2006) (0)
#683 A phase I dose escalation study of intrathecal cytarabine liposome injection (DepoCytTM) in pediatric patients with advanced meningeal malignancies (1998) (0)
Issue Information (2014) (0)
Abstract B02: Bortezomib-resistant pediatric acute myeloid leukemia cell lines derived from Down syndrome patients are sensitive to disulfiram (2016) (0)
Cancer Cell Line Selection for Doxorubicin Resistance in a Human Lung Vitro in Resistance Precedes P-Glycoprotein Expression during Non-P-Glycoprotein mediated Mechanism for Multidrug (2006) (0)
Loss in Chromosome 11q Identifies Tumors with Increased risk for Metastatic Relapses in Localized and 4S NeuroblastomaSpitz R, Hero B, Simon T, et al (Univ Children's Hosp, Köln, Germany) Clin Cancer Res 12:3368–3373, 2006§ (2007) (0)
Chapter 66 – Histiocytic Disorders of the Lung (2006) (0)
From Roentgen and Curie to Ras and Cyclins (2004) (0)
Issue Information (2014) (0)
Amifostine Protects Against Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma (2009) (0)
Faculty Opinions recommendation of KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. (2006) (0)
Late-Occurring Stroke Among Long-Term Survivors of Childhood Leukemia and Brain Tumors: A Report From the Childhood Cancer Survivor Study (2008) (0)
Acute myelogenous leukemia in children (2013) (0)
Comprar Year Book of Oncology 2011 | Robert J. Arceci | 9780323084208 | Mosby (2011) (0)
The MMSET Gene Contributes to the Growth, Adhesion, and Tumorigencitiy of t(4;14) Multiple Myeloma Cells. (2007) (0)
The challenge and cost of patient safety. (2003) (0)
1144 POSTER Using Single-cell Network Profiling (SCNP) Signatures to Predict Response to Induction Therapy and Relapse Risk in Pediatric Patients With Acute Myeloid Leukemia (AML) (2011) (0)
Mechanism of relapse in pediatric acute lymphoblastic leukemia (2009) (0)
The Fanconi anemia cell line HSC 536 N is not sensitive to interferon-g and does not cleave PARP in response to Fas-mediated cell killing (2002) (0)
Biologically risk directed therapy for improved trial development and outcomes in patients with AML (2002) (0)
Response to Letters to the Editor From the Editor-in-Chief (2000) (0)
Comments from the Editor-in-Chief. (1999) (0)
Diamond-Blackfan anemia Abnormalities of the large ribosomal subunit protein, Rpl35a, in (2011) (0)
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression (2010) (0)
Temporal Trends in Cause-Specific Late Mortality Among 5-Year Survivors of Childhood Cancer (2010) (0)
Inhibition of a New Differentiation Pathway in Neuroblastoma by Copy Number Defects of N-myc, CDc42, and nm23 GenesValentijn LJ, Koppen A, van Asperen R, et al (Univ of Amsterdam) Cancer Res 65:3136-3145, 2005§ (2006) (0)
Faculty Opinions recommendation of Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and Neutropenia--a systemic review and meta-analysis. (2012) (0)
Abstract 3766: Targeting promoter regions of c-Myc and Bcl-2 in AML cells using G-quadruplex interacting drugs (2016) (0)
JPHO: Survey, suggestions and strategies (2002) (0)
Fever and neutropenia: changing patterns of medical practice. (2000) (0)
Abstract 3982: Repurposing disulfiram for treatment of relapsed/refractory acute myeloid leukemia (2014) (0)
Phase II Study of Intermediate-Dose Cytarabine in Patients With Relapsed or Refractory Ewing Sarcoma: A Report From the Children's Oncology Group (2009) (0)
Response to Paclitaxel, Topotecan, and Topotecan-Cyclophosphamide in Children With Untreated Disseminated Neuroblastoma Treated in an Upfront Phase II Investigational Window: A Pediatric Oncology Group StudyKretschmar CS, Kletzel M, Murray K, et al (Boston Floating Hosp for Infants and Children; Chi (2006) (0)
Modeling First-Hit Functions of the t(12;21) TEL-AML1 Translocation in MiceTsuzuki S, Seto M, Greaves M, et al (Aichi Cancer Ctr Research Inst, Nagoya, Japan; Chester Beatty Labs, London; Oxford Univ, England) Proc Natl Acad Sci U S A 101:8443-8448, 2004§ (2006) (0)
Minimizing Therapy for Patients with Acute Promyelocytic Leukemia: Efficacy of Single Cycle of Arsenic-Based Consolidation Therapy. (2008) (0)
Passing the Torch While it still Shines (2003) (0)
Abstract 94: DrugPath: A web database for academic investigators to identify drugs that match oncology molecular targets (2010) (0)
Skip Metastases in Osteosarcoma: Experience of the Cooperative Osteosarcoma Study GroupKager L, Zoubek A, Kastner U, et al (Univ Hosp Vienna; Univ Hosp Zürich, Switzerland; Diagnostic Radiology, Hamburg, Germany; et al) J Clin Oncol 24:535–1541, 2006§ (2007) (0)
Plenary paper Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia (2008) (0)
Faculty Opinions recommendation of FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. (2010) (0)
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation (2010) (0)
Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial (2008) (0)
An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
Abstract B06: Overcoming hypoxia-induced resistance is essential for effective survivin targeting in acute myeloid leukemia (2018) (0)
Somatic CEBPA Mutations Are a Frequent Second Event in Families With Germline CEBPA Mutations and Familial Acute Myeloid Leukemia (2009) (0)
Hemophagocytic Lymphohistiocytosis: Diagnosis and Management Challenges (2016) (0)
Curing Pediatric Cancers: A Success Story Reconsidered (2007) (0)
Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia (2012) (0)
Abstract 1441: Role of a long non-coding RNA in oncogenesis of Ewing sarcoma (2012) (0)
Comparison of Two New Classifications for Pediatric Myelodysplastic and Myeloproliferative DisordersOcchipinti E, Correa H, Yu L, et al (Louisiana State Univ, New Orleans) Pediatr Blood Cancer 44:240-244, 2005§ (2006) (0)
Targeted Therapeutic Approaches for AML (2010) (0)
Ewing Sarcomas With p53 Mutation or p16/p14ARF Homozygous Deletion: A Highly Lethal Subset Association With Poor ChemoresponseHuang H-Y, Illei PB, Zhao Z, et al (Mem Sloan-Kettering Cancer Ctr, New York J Clin Oncol 23:548-558, 2005§ (2006) (0)
Synergistic and antagonistic AML cell type-specific responses to 5-AZA-2’-Deoxycytidine and 1-H-D-Arabinofuranosylcytosine (2014) (0)
RNAi screen for rapid therapeutic target identification in leukemia patients (2009) (0)
Serial Evaluation of Academic and Behavioral Outcome After Treatment With Cranial Radiation in ChildhoodMabbott DJ, Spiegler BJ, Greenberg ML, et al (Univ of Toronto J Clin Oncol 23:2256-2263, 2005§ (2006) (0)
Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials (2009) (0)
An EBF3-Mediated Transcriptional Program That Induces Cell Cycle Arrest and Apoptosis (2008) (0)
Phase I Trial and Pharmacokinetics Study of the Farnesyltransferase Inhibitor Tipifarnib in Children With Refractory Solid Tumors or Neurofibromatosis Type I and Plexiform Neurofibromas (2007) (0)
Genome-Wide Analyses Identify Recurrent Amplifications of Receptor Tyrosine Kinases and Cell-Cycle Regulatory Genes in Diffuse Intrinsic Pontine Glioma (2012) (0)
Prognostic Importance of Histone Methyltransferase MLL5 Expression in Acute Myeloid Leukemia (2011) (0)
A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia (2011) (0)
Abstract 3923: A role for fibroblast growth factor receptors in growth of atypical teratoid rhabdoid tumor cells and as potential therapeutic targets (2015) (0)
Acute myeloid leukemia commentary (2013) (0)
Multidrug Resistance Reversal Utilizing Mitoxantrone, Etoposide and Continuous Infusion Cyclosporine in Pediatric ANLL (1994) (0)
Historical Perspective and Current Challenges of Cancer Genomics (2014) (0)
Chromosome 1p and 11q Deletions and Outcome in NeuroblastomaAttiyeh EF, for the Children's Oncology Group (Univ of Pennsylvania, Philadelphia; Children's Ocology Group, Arcadia, Calif; Harvard Med School, Boston) N Engl J Med 353:2243–2253, 2005§ (2007) (0)
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles (2011) (0)
Leukemia Bearing a Novel t ( 8 ; 14 ) ( q 24 ; qll ) Translocation Demonstrates Spontaneous In Vitro Natural Killer-Like Activity (2003) (0)
Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and MLL Gene Rearrangements: A Report From the Children's Oncology Group (2011) (0)
HTLV-HI Infection After Bone Marrow Transplantation (2005) (0)
Efficacy of Complete Resection for High-Risk Neuroblastoma: A Children's Cancer Group StudyAdkins ES, Sawin R, Gerbing RB, et al (Univ of South Carolina, Columbia; Children's Hosp, Seattle; Children's Oncology Group, Arcadia, Calif; et al) J Pediatr Surg 39:931-936, 2004§ (2006) (0)
Pharmacogenomic Prediction of Anthracycline-Induced Cardiotoxicity in Children (2012) (0)
Abstract 5583: Integrative genomic analyses on pediatric acute myeloid leukemia (2014) (0)
Comprar Molecularly Targeted Therapy for Childhood Cancer | Houghton, Peter J. | 9780387690605 | Springer (2010) (0)
Comprar Pediatric Hematology | Glennys Howarth | 9781405134002 | Wiley (2009) (0)
TBI and Allogeneic BMT Do Not Appear To Hinder Growth in Pediatirc Patients with AML Treated on POG 9421 (Now Children’s Oncology Group). (2006) (0)
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML (2009) (0)
Selective and Titratable Effects On AML Genome Wide Methylation Patterning, Transcription and Clonogenicity Using Very Low Concentrations of 5-Aza-2'deoxycytidine. (2009) (0)
Abstract B6: Human genome contains a large number of very long intergenic transcribed regions, some of which are associated with cancer outcome (2012) (0)
Faculty Opinions recommendation of Undifferentiated hematopoietic cells are characterized by a genome-wide undermethylation dip around the transcription start site and a hierarchical epigenetic plasticity. (2010) (0)
The incidence and clinical significance of nucleophosmin mutations in (2013) (0)
Loss of Heterozygosity in Childhood Acute Lymphoblastic Leukemia Detected by Genome-Wide Microarray Single Nucleotide Polymorphism Analysis (2006) (0)
Faculty Opinions recommendation of EZH2 is essential for glioblastoma cancer stem cell maintenance. (2010) (0)
Abstract B18: The transcribed non-coding genome modulates the biology of Ewing sarcoma family of tumors (2012) (0)
Pediatric Blood & Cancer: The first year (2004) (0)
Extracellular ATP reverses drug efflux mediated by the P-glycoprotein (1993) (0)
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinib (2010) (0)
Fetal growth and acute childhood leukemia: looking beyond birth weight (2008) (0)
#653 Chromosomal mapping of a new helicase gene (1998) (0)
Abstract B04: Direct downregulation of MYC in AML cells using promoter G-quadruplex interacting small molecules (2018) (0)
Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood (2011) (0)
Treatment, Outcomes, and Challenges of Newly Diagnosed AML in Children and Adolescents (2007) (0)
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome (2010) (0)
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis (2011) (0)
Gene Expression Profiling of Gliomas Strongly Predicts Survival (2006) (0)
Comments From the Editor‐in-Chief (1998) (0)
Autoimmune Lymphoproliferative Syndrome Like Disease With Somatic KRAS Mutation (2011) (0)
Abstract 4766: Establishment of drug sensitivity and resistance testing using focused drug libraries to develop targeted therapies for patients with leukemia (2016) (0)
Issue Information (2014) (0)
P-083 5q-syndrome or diamond blackfan anemia: The perplexing diagnostic puzzle of red cell aplasia (2013) (0)
HE PATOLOGY Elsew here (1993) (0)
Faculty Opinions recommendation of Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. (2009) (0)
Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia (2011) (0)
Isolation, expansion, cloning and characterization of specific anti-tumor cytolytic T-cell lymphocytes (CTL) derived from a patient with ewing's sarcoma (ES) (2000) (0)
Bortezomib Reverses a Post-Translational Mechanism of Tumorigenesis for Patched1 Haploinsufficiency in Medulloblastoma (2009) (0)
Resistance Associated with a Novel MAP 2 K 1 Mutation in a Patient with Langerhans Cell Histiocytosis (2019) (0)
EbB4 is a novel driver of metastasis and anoikis resistance in Ewing's sarcoma (2012) (0)
RED CELLS , IRON , AND ERYTHROPOIESIS Diminutive somatic deletions in the 5 q region lead to a phenotype atypical of classical 5 q 2 syndrome (2013) (0)
PASG, an SNF2 family member essential for proliferation of murine lymphocytes and altered in leukemia, is expressed in the proliferatfve compartments of human myeloid and lymphoid progenitors (2000) (0)
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial (2011) (0)
Shh Pathway Activity is Down-Regulated in Cultured Medulloblastoma Cells: Implications for Preclinical StudiesSasai K, Romer JT, Lee Y, et al (Saint Jude Children's Research Hosp, Memphis, Tenn) Cancer Res 66:4215–4222, 2006§ (2007) (0)
Patient and disease characteristics of women with acute myelogenous leukemia (AML) and a history of breast cancer (BC). (2010) (0)
Integrative Network Analysis of Pediatric AML Whole Genomes, cDNA Expression and Clinical Data Elements Reveals Shared As Well As t(8;21), Inv16 and MLL Specific Pathways; A Report From COG/NCI Target AML Initiative (2012) (0)
Primum non nocere. Authors' reply (2006) (0)
Gene Expression Profiling for Survival Prediction in Pediatric Rhabdomyosarcomas: A Report From the Children's Oncology Group (2010) (0)
cooperative trials for de novo AML patients with core binding factor AML enrolled on serial pediatric mutations in pediatric KIT Prevalence and prognostic significance of (2011) (0)
Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols. (2007) (0)
Issue Information (2015) (0)
Abstract 4087: Large intergenic noncoding RNAs associated with Ewing sarcoma family of tumors (2010) (0)
Yeast Models of Diamond Blackfan Anemia and Shwachman Diamond Syndrome Differ in Their Effect on the Synthesis and Function of Ribosomal Subunits. (2008) (0)
Myeloid Leukemias-Current and Future Approaches to Targeted and Individualized Therapies (2011) (0)
Prognostic Significance of Tumor Response at the End of Therapy in Group III Rhabdomyosarcoma: A Report From the Children's Oncology Group (2010) (0)
Demographic, clinical and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trial (2011) (0)
Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT ExperienceJourdan E, Boiron J-M, Dastugue N, et al (Centre Hospitalier Universitaire (CHU), Nîmes, France; Hôpital Haut-Levêque, (2007) (0)
Abstract 2646: Ewing sarcoma-derived iPS cell lines are resistant to chemotherapy but exhibit EWS-FLI1-independent, increased rapamycin sensitivity. (2013) (0)
Clinical relevance of P-gp expression in pediatric myeloid leukemia [11] (2006) (0)
Anaplastic Lymphoma Kinase Aberrations in Rhabdomyosarcoma: Clinical and Prognostic Implications (2012) (0)
Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients With Neuroblastoma (2006) (0)
Treatment of Childhood Acute Myeloid Leukemia (2003) (0)
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia (2012) (0)
Clinical Course and Outcome in Children With Acute Lymphoblastic Leukemia and Asparaginase-Associated Pancreatitis (2009) (0)
Abstract 1823: Influence of a long non-coding RNA on epigenetic, genetic and phenotypic changes in Ewing sarcoma. (2013) (0)
Hodgkin's Lymphoma in Adolescents (2007) (0)
Obesity and outcome in pediatric acute lymphoblastic leukemia (2008) (0)
Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95 (2008) (0)
Mortality in Overweight and Underweight Children With Acute Myeloid LeukemiaLange BJ, Gerbing RB, Feusner J, et al (Children's Hosp of Philadelphia; Children's Oncology Group, Arcadia, Calif; Children's Hosp of Oakland, Calif; et al) JAMA 293:203–211, 2005§ (2006) (0)
Abstract 2791: Hypoxia selectively confers resistance to the survivin-targeting compound YM155 in acute myeloid leukemia and Ewings sarcoma cell lines (2016) (0)
Contents page (2015) (0)
Drug Resistance in Acute Leukemia (2003) (0)
Imatinib Mesylate (STI571) for Treatment of Children With Philadelphia Chromosome-Positive Leukemia: Results From a Children's Oncology Group Phase 1 StudyChampagne MA, Capdeville R, Krailo M, et al (Hôptial Ste-Justine, Montréal; Children's Oncology Group, Arcadia, AB, Canada; Baylor College of Med (2006) (0)
Pediatric Blood & Cancer—A progress report (2005) (0)
Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in MedulloblastomasFernandez-Teijeiro A, Betensky RA, Sturla LM, et al (Children's Hosp, Boston; Harvard Med School, Boston; Harvard School of Public Health, Boston; et al J Clin Oncol 22:994-998, 2004§ (2006) (0)
Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457—A Report From the Children's Oncology GroupBernstein ML, Devidas M, Lafreniere D, et al (Hôpital Sainte-Justine, Montreal; Children (2007) (0)
Abstract 4973: Long non-coding RNA promotes metastatic behavior in Ewing sarcoma (2014) (0)
Fibroblast growth factor blocks Sonic hedgehog signaling in neuronal precursors and tumor cells (2008) (0)
Abstract 3422: Synthetic lethal siRNA screening reveals novel modifiers of insulin-like growth factor-1 receptor (IGF1R) inhibitor activity in childhood sarcomas (2010) (0)
Significance of MYCN Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database (2009) (0)
Issue Information (2014) (0)
Abstract A43: Therapeutic importance of a long noncoding RNA in Ewing sarcoma (2014) (0)
Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Robert J. Arceci?

Robert J. Arceci is affiliated with the following schools:

Emory University
Albert Einstein College of Medicine
University of Arizona
Johns Hopkins University
University of Rochester
Harvard University